Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Gracell: Speeding up CAR T cells

Gracell's manufacturing platform could accelerate production of CAR T cell therapies from two weeks to one day

Hongjiang Li, Staff Writer
June 13, 2019 9:41 PM UTC

With a platform that could reduce the manufacturing time of autologous CAR T cells from two weeks to one day, Gracell is lining up a set of therapies it could produce with the method.

Gracell Biotechnologies Co. Ltd. founder, Chairman and CEO William Cao told BioCentury that the company, which emerged from stealth in February with a $85 million series B round led by Temasek, plans to address the lengthy production times and high costs of CAR T cell therapies...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Gilead Sciences Inc.

Gracell Biotechnologies Inc.

Novartis AG

Ziopharm Oncology Inc.